Angiomax bivalirudin: Phase IIIb results; marketed to treat unstable angina in patients undergoing angioplasty in the U.S. and New Zealand; under review in Euro

There was no difference between patients on Angiomax and those given heparin on the primary endpoint of 30-day mortality in MDCO's HERO-2 trial. The international open label Phase IIIb trial was in 17...